{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:04:52Z","timestamp":1792119892806,"version":"4.4.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/mjt.0b013e31828d455b","type":"journal-article","created":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T13:29:18Z","timestamp":1366723758000},"page":"235-246","source":"Crossref","is-referenced-by-count":32,"title":["Cardiovascular Safety of Varenicline"],"prefix":"10.1097","volume":"20","author":[{"given":"James H.","family":"Ware","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Vetrovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Van Tosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Yunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Arteaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Borer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210202","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/bmj.2.4682.739","article-title":"Smoking and carcinoma of the lung; preliminary report.","volume":"2","author":"Doll","year":"1950","journal-title":"Br Med J"},{"key":"R3-3-20210202","first-page":"625","article-title":"Annual smoking-attributable mortality, years of potential life lost, and productivity lossesUnited States, 1997-2001.","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R5-3-20210202","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":". Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.","volume":"48","author":"Coe","year":"2005","journal-title":"J Med Chem"},{"key":"R6-3-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/CIRCULATIONAHA.109.869008","article-title":". Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.","volume":"121","author":"Rigotti","year":"2010","journal-title":"Circulation"},{"key":"R7-3-20210202","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1503\/cmaj.110218","article-title":". Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.","volume":"183","author":"Singh","year":"2011","journal-title":"CMAJ"},{"key":"R8-3-20210202","doi-asserted-by":"crossref","first-page":"e2856","DOI":"10.1136\/bmj.e2856","article-title":"Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.","volume":"344","author":"Prochaska","year":"2012","journal-title":"BMJ"},{"key":"R11-3-20210202","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.clinthera.2011.04.013","article-title":". Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.","volume":"33","author":"Bolliger","year":"2011","journal-title":"Clin Ther"},{"key":"R12-3-20210202","doi-asserted-by":"crossref","first-page":"c6549","DOI":"10.1136\/bmj.c6549","article-title":". Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial.","volume":"341","author":"Fagerstrom","year":"2010","journal-title":"BMJ"},{"key":"R13-3-20210202","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.biopsych.2010.12.005","article-title":". A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo.","volume":"69","author":"Garza","year":"2011","journal-title":"Biol Psychiatry"},{"key":"R14-3-20210202","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":". Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.","volume":"296","author":"Gonzales","year":"2006","journal-title":"JAMA"},{"key":"R15-3-20210202","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":". Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"key":"R16-3-20210202","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.clinthera.2007.06.012","article-title":". Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.","volume":"29","author":"Nakamura","year":"2007","journal-title":"Clin Ther"},{"key":"R17-3-20210202","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1185\/03007990802177523","article-title":". The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial.","volume":"24","author":"Niaura","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R18-3-20210202","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/archinte.166.15.1571","article-title":". Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.","volume":"166","author":"Oncken","year":"2006","journal-title":"Arch Intern Med"},{"key":"R19-3-20210202","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ntr\/ntr220","article-title":". A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates.","volume":"14","author":"Rennard","year":"2012","journal-title":"Nicotine Tob Res"},{"key":"R20-3-20210202","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1378\/chest.10-0865","article-title":". Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.","volume":"139","author":"Tashkin","year":"2011","journal-title":"Chest"},{"key":"R21-3-20210202","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.clinthera.2007.06.011","article-title":". A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.","volume":"29","author":"Tsai","year":"2007","journal-title":"Clin Ther"},{"key":"R22-3-20210202","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1440-1843.2008.01476.x","article-title":". Varenicline for smoking cessation: a placebo-controlled, randomized study.","volume":"14","author":"Wang","year":"2009","journal-title":"Respirology"},{"key":"R23-3-20210202","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.11m07522","article-title":". A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.","volume":"73","author":"Williams","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"R24-3-20210202","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1185\/030079907X182185","article-title":". A double-blind study evaluating the long-term safety of varenicline for smoking cessation.","volume":"23","author":"Williams","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R25-3-20210202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.296.1.64","article-title":". Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.","volume":"296","author":"Tonstad","year":"2006","journal-title":"JAMA"},{"key":"R27-3-20210202","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":". Universal definition of myocardial infarction.","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"key":"R28-3-20210202","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0091270006292624","article-title":". Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.","volume":"46","author":"Faessel","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R29-3-20210202","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1503\/cmaj.111-2073","article-title":"Varenicline: cardiovascular safety.","volume":"183","author":"Samuels","year":"2011","journal-title":"CMAJ"},{"key":"R30-3-20210202","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1503\/cmaj.111-2070","article-title":"Varenicline: quantifying the risk.","volume":"183","author":"Squire","year":"2011","journal-title":"CMAJ"},{"key":"R31-3-20210202","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1503\/cmaj.111-2063","article-title":"Varenicline: quantifying the risk.","volume":"183","author":"Takagi","year":"2011","journal-title":"CMAJ"},{"key":"R32-3-20210202","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1503\/cmaj.111-2064","article-title":"Varenicline: quantifying the risk.","volume":"183","author":"Woods","year":"2011","journal-title":"CMAJ"},{"key":"R33-3-20210202","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.athoracsur.2012.08.073","article-title":". Heavy smoking before coronary surgical procedures affects the native matrix metalloproteinase-2 and matrix metalloproteinase-9 gene expression in saphenous vein conduits.","volume":"95","author":"Yongxin","year":"2013","journal-title":"Ann Thorac Surg"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e31828d455b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:37:52Z","timestamp":1620963472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201305000-00003"}},"subtitle":["Patient-Level Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31828d455b","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}